


National Clinical Audit and Patient Outcomes Programme (NCAPOP) Infographics compendium


Q1 (April - June 2023), updated 06/11/2023

ſ	PUBLICATION	HEALTHCARE AREA	TYPE	PROJECT NAME	LEAD PROVIDER	FULL REPORT TITLE	HQIP WEBLINK TO REPORT	DOC NUMBER
	DATE							
	2023/04/12	Cancer	Audit	NLCA - National Lung Cancer Audit	RCP: Royal College of Physicians	NLCA: State of the Nation Report 2023	https://www.hqip.org.uk/resource/lung-cancer-ncla-apr23/#.ZDaa2XbMJPY	0.01





Diagnosis & staging








Treatment allocation











Data quality







Diagnosis & staging



73

patients were diagnosed with lung cancer in 2021



of patients with stage I/II disease, performance status (PS) 0-1 had pathological confirmation of their diagnosis: 83% in 2020 and 86% in 2019



of patients* were assessed at diagnosis by a lung cancer clinical nurse specialist: 93% in 2020 and 90% in 2019

2,067 in 2020 2,240 in 2019



of patients presented with stage IV disease: 49% in 2020 and 48% in 2019



>90% Audit standard

age at diagnosis (median)



of patients were diagnosed via emergency presentation: 28% in 2020 and 29% in 2019

Treatment allocation



of patients with NSCLC had surgical



>17% Audit standard

11% in 2020 16% in 2019

Chemotherapy for small cell lung cancer (SCLC)





>70% Audit standard

58% in 2020 65% in 2019

Treatment with curative intent



of patients with NSCLC (stage I/II, PS 0-2) received treatment with curative





66% in 2020 73% in 2019

of patients with NSCLC (stage IIIA, PS 0-2) received treatment with curative intent***



N/A

47% in 2020 55% in 2019

***surgery, radical radiotherapy or multimodal combination with chemotherapy

Systemic anticancer treatment



**surgery or radical radiotherapy

of patients with NSCLC (stage IIIB - IV, PS 0-1) received systemic anticancer



≥65% Audit standard

52% in 2020 54% in 2019

Survival outcomes

15,192 patients were diagnosed between 1 January and 30 June 2021. For these patients:

Median survival

One year survival

222 days

224 days in 2020 235 days in 2019

39%

40% in 2020 **42%** in 2019

Data quality

Completeness of key routine data items****

Stage

Performance status

Morphology

100%

Basis of diagnosis

90%

Audit standard

90% Audit standard

CNS at diagnosis

*****information on smoking status unavailable

90% 98% Audit standard

90% Audit standard 100%

